| Quarterly Financials | Mar 2015 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 830 | 1,044 | 1,404 | 1,394 | 1,308 | 1,193 | 1,493 | 1,438 | 1,466 | 1,748 | 1,763 | 1,721 | 1,812 | 1,997 | 2,007 | 2,510 | 2,571 | 2,343 | 1,935 | 1,821 | 2,017 | 1,859 | 1,995 | 1,950 | 2,382 | 2,197 | 2,444 | 2,401 |
| Expenses | 501 | 643 | 802 | 827 | 851 | 776 | 955 | 902 | 945 | 1,030 | 1,008 | 1,010 | 1,072 | 1,109 | 1,169 | 1,396 | 1,414 | 1,406 | 1,234 | 1,299 | 1,464 | 1,274 | 1,430 | 1,366 | 1,572 | 1,496 | 1,622 | 1,576 |
| EBITDA | 328 | 401 | 602 | 567 | 457 | 418 | 538 | 536 | 521 | 717 | 755 | 711 | 740 | 888 | 837 | 1,114 | 1,157 | 937 | 701 | 522 | 553 | 585 | 565 | 584 | 810 | 701 | 822 | 825 |
| Operating Profit % | 39 % | 35 % | 39 % | 39 % | 33 % | 33 % | 34 % | 35 % | 32 % | 40 % | 42 % | 41 % | 40 % | 43 % | 41 % | 44 % | 44 % | 38 % | 33 % | 24 % | 25 % | 28 % | 25 % | 26 % | 32 % | 29 % | 31 % | 32 % |
| Depreciation | 45 | 42 | 42 | 43 | 42 | 44 | 46 | 47 | 50 | 56 | 61 | 68 | 70 | 73 | 77 | 80 | 81 | 85 | 86 | 87 | 87 | 93 | 95 | 95 | 95 | 97 | 99 | 99 |
| Interest | 1 | 1 | 0 | 3 | 0 | 0 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 |
| Profit Before Tax | 286 | 359 | 559 | 522 | 415 | 373 | 488 | 487 | 471 | 661 | 694 | 642 | 670 | 815 | 760 | 1,034 | 1,076 | 852 | 615 | 435 | 466 | 492 | 469 | 489 | 713 | 604 | 722 | 726 |
| Tax | 54 | 91 | 156 | 133 | 123 | 101 | 131 | 128 | 83 | 169 | 174 | 172 | 168 | 257 | 153 | 131 | 181 | 150 | 122 | 129 | 145 | 136 | 121 | 131 | 175 | 174 | 212 | 137 |
| Net Profit | 232 | 268 | 404 | 389 | 292 | 272 | 357 | 359 | 388 | 492 | 520 | 471 | 502 | 557 | 607 | 902 | 895 | 702 | 493 | 306 | 321 | 356 | 348 | 358 | 538 | 430 | 510 | 589 |
| EPS in ₹ | 17.40 | 10.08 | 15.21 | 14.67 | 11.00 | 10.26 | 13.44 | 13.53 | 14.62 | 18.54 | 19.57 | 17.73 | 18.91 | 20.99 | 22.84 | 33.99 | 33.70 | 26.44 | 18.60 | 11.56 | 12.09 | 13.41 | 13.11 | 13.50 | 20.25 | 16.20 | 19.20 | 22.20 |
Divis Laboratories
5,589.30
+203.15
(3.77%)
Market Cap
1,48,378.35 Cr
EPS
60.27
PE Ratio
69.15
Dividend Yield
0.56 %
Industry
Healthcare52 Week High
6,285.45
52 Week Low
3,641.00
PB Ratio
10.42
Debt to Equity
0.00
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from22 analysts
Company News
View All News
Divis Laboratories Reports Significant Increase in Exports3 days ago
Divis Laboratories, an Indian CDMO (Contract Development and Manufacturing Organization) in the pharmaceutical sector, has reported a substantial increase in exports. The company's exports reached $85 million, marking a 22% year-over-year growth. Additionally, the fourth quarter exports also showed a significant jump of 23%.
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,687.55 | #1 4,04,899.77 | 33.61 | #1 49,887.20 | 12.06 | #1 9,648 | 13.77 | 47.60 | |
5,589.30 | #2 1,48,378.35 | #10 69.15 | #9 8,184.00 | #10 0.89 | #9 1,600 | #1 64.53 | 47.92 | |
1,463.05 | 1,18,158.10 | 22.92 | 26,520.70 | 14.17 | 4,155 | 47.38 | 50.89 | |
3,129.00 | 1,05,899.58 | 56.83 | 10,785.70 | 11.59 | 1,656 | 13.54 | 45.29 | |
2,350.50 | 96,976.58 | 46.77 | 10,615.60 | 19.57 | 1,942 | -16.38 | 48.68 | |
1,109.50 | 92,582.82 | #1 17.01 | 28,905.40 | 12.36 | 5,578 | 1.69 | 40.66 | |
1,969.25 | 89,904.33 | 30.58 | 20,141.50 | #1 19.94 | 1,936 | 38.82 | 46.62 | |
868.85 | 87,426.64 | 18.74 | 19,831.50 | 13.82 | 3,831 | 29.92 | 44.56 | |
29,641.10 | 62,985.27 | 46.40 | 6,097.20 | 10.80 | 1,201 | 16.01 | 48.36 | |
1,082.45 | 62,868.87 | 17.41 | 29,559.20 | 17.55 | 3,169 | -10.04 | 41.61 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
0.89 %
Net Income Growth
-12.28 %
Cash Flow Change
-48.72 %
ROE
-17.49 %
ROCE
-14.12 %
EBITDA Margin (Avg.)
-7.03 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 4,411 | 4,902 | 6,159 | 6,786 | 8,038 | 8,536 | 10,774 | 13,375 | 14,439 | 15,470 |
| Fixed Assets | 1,309 | 1,439 | 1,559 | 1,996 | 2,088 | 2,782 | 3,704 | 4,325 | 4,722 | 4,739 |
| Current Assets | 2,772 | 3,027 | 4,011 | 4,535 | 4,650 | 4,680 | 6,175 | 8,352 | 9,312 | 9,675 |
| Capital Work in Progress | 218 | 264 | 444 | 120 | 492 | 920 | 711 | 470 | 212 | 778 |
| Investments | 733 | 803 | 1,631 | 1,889 | 1,946 | 971 | 0 | 72 | 77 | 82 |
| Other Assets | 2,151 | 2,397 | 2,525 | 2,781 | 3,513 | 3,863 | 6,360 | 8,508 | 9,428 | 9,871 |
| Total Liabilities | 4,411 | 4,902 | 6,159 | 6,786 | 8,038 | 8,536 | 10,774 | 13,375 | 14,439 | 15,470 |
| Current Liabilities | 776 | 520 | 660 | 653 | 847 | 927 | 1,113 | 1,196 | 1,101 | 1,278 |
| Non Current Liabilities | 141 | 89 | 142 | 208 | 234 | 299 | 367 | 451 | 571 | 621 |
| Total Equity | 3,495 | 4,293 | 5,357 | 5,925 | 6,957 | 7,310 | 9,295 | 11,728 | 12,767 | 13,571 |
| Reserve & Surplus | 3,469 | 4,240 | 5,304 | 5,872 | 6,904 | 7,257 | 9,242 | 11,675 | 12,714 | 13,518 |
| Share Capital | 27 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 3 | 0 | 13 | -17 | 23 | 41 | 1,987 | -816 | -1,045 | 193 |
| Investing Activities | -521 | -406 | -1,140 | -478 | -685 | -84 | 75 | -2,195 | -2,707 | -269 |
| Operating Activities | 826 | 1,038 | 1,150 | 776 | 954 | 1,216 | 1,947 | 1,912 | 2,459 | 1,261 |
| Financing Activities | -303 | -631 | 2 | -314 | -246 | -1,091 | -35 | -532 | -797 | -799 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 51.95 % | 51.95 % | 51.95 % | 51.95 % | 51.94 % | 51.94 % | 51.94 % | 51.94 % | 51.94 % | 51.93 % | 51.93 % | 51.92 % | 51.92 % | 51.90 % | 51.89 % | 51.89 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 14.86 % | 14.68 % | 16.16 % | 17.25 % | 17.99 % |
| DIIs | 12.64 % | 12.61 % | 12.64 % | 13.40 % | 13.73 % | 13.93 % | 19.54 % | 20.67 % | 21.07 % | 21.23 % | 20.97 % | 21.88 % | 22.21 % | 21.77 % | 21.06 % | 20.54 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 9.28 % | 8.81 % | 8.87 % | 9.01 % | 9.27 % | 9.53 % | 9.20 % | 9.53 % | 9.61 % | 9.28 % | 9.02 % | 8.85 % | 8.69 % | 7.77 % | 7.41 % | 7.32 % |
| Others | 26.14 % | 26.64 % | 26.55 % | 25.64 % | 25.06 % | 24.59 % | 19.31 % | 17.86 % | 17.37 % | 17.56 % | 18.08 % | 2.48 % | 2.50 % | 2.41 % | 2.39 % | 2.26 % |
| No of Share Holders | 2,08,203 | 1,93,883 | 2,23,403 | 2,74,505 | 3,09,397 | 3,46,905 | 3,79,257 | 4,14,847 | 4,33,621 | 4,02,155 | 3,73,860 | 3,54,482 | 3,47,629 | 2,98,310 | 2,78,899 | 2,80,601 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 10 | 10 | 16 | 16 | 20 | 30 | 0.00 | 30 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.92 | 0.59 | 0.8 | 0.44 | 0.45 | 1.06 | 0.00 | 0.52 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
6 days ago
6 days agoClosure of Trading WindowMar 31, 2025
Mar 31, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMar 31, 2025
Mar 31, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 07, 2025
Mar 07, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 07, 2025
Mar 07, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 21, 2025
Feb 21, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 07, 2025
Feb 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 05, 2025
Feb 05, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 03, 2025
Feb 03, 2025Integrated Filing (Financial)Feb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 03, 2025
Feb 03, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On February 03 2025Feb 03, 2025
Feb 03, 2025Outcome Of Board Meeting Held On February 03 2025 - Financial Results For The Quarter And Nine Months Ended December 30 2024Feb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 28, 2025
Jan 28, 2025Board Meeting Intimation for Intimation Of Board MeetingJan 23, 2025
Jan 23, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 13, 2025
Jan 13, 2025Initmation Of Commencement Of Commercial Operations At Unit III Greenfield Project At Kakinada Andhra Pradesh In Phased MannerJan 02, 2025
Jan 02, 2025Closure of Trading WindowDec 31, 2024
Dec 31, 2024Resubmission - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015Dec 05, 2024
Dec 05, 2024Clarification /Confirmation On News Item Appearing In 'Media/Publication' Under Regulation 30 Of SEBI (LODR) Regulations, 2015Dec 05, 2024
Dec 05, 2024Intimation Of Action(S) Taken Or Orders PassedDec 04, 2024
Dec 04, 2024Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 15, 2024
Nov 15, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 11, 2024
Nov 11, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 09, 2024
Nov 09, 2024Board Meeting Outcome for Outcome Of Board Meeting - Submission Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024Nov 09, 2024
Nov 09, 2024Submission Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024Nov 09, 2024
Nov 09, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 01, 2024
Nov 01, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 01, 2024
Nov 01, 2024Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2024.Oct 29, 2024
Oct 29, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 10, 2024
Oct 10, 2024Closure of Trading WindowSep 30, 2024
Sep 30, 2024Announcement under Regulation 30 (LODR)-Credit RatingSep 14, 2024
Sep 14, 2024Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportAug 12, 2024
Aug 12, 2024Shareholder Meeting / Postal Ballot-Outcome of AGMAug 12, 2024
Aug 12, 2024Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 08, 2024
Aug 08, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 05, 2024
Aug 05, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 03, 2024
Aug 03, 2024Board Meeting Outcome for Outcome Of Board Meeting - Submission Of Unaudited Financial Results For The Quarter Ended June 30, 2024Aug 03, 2024
Aug 03, 2024Outcome Of Board Meeting - Submission Of Unaudited Financial Results For The Quarter Ended June 30, 2024Aug 03, 2024
Aug 03, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 27, 2024
Jul 27, 2024Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2024.Jul 25, 2024
Jul 25, 2024US-FDA Inspection Of Company'S Unit-II Manufacturing Facility At Visakhapatnam, Andhra PradeshJul 19, 2024
Jul 19, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Jul 17, 2024
Jul 17, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 17, 2024
Jul 17, 2024Business Responsibility and Sustainability Reporting (BRSR)Jul 15, 2024
Jul 15, 2024Notice Of 34Th Annual General Meeting To Be Held On Monday, August 12, 2024 At 10.00 A.M. IST Through Video Conferencing (VC) / Other Audio-Visual Means (OAVM)Jul 15, 2024
Jul 15, 2024Reg. 34 (1) Annual Report.Jul 15, 2024
Jul 15, 2024Technical Indicators
RSI(14)
Neutral 47.92
ATR(14)
Volatile 212.57
STOCH(9,6)
Neutral 41.36
STOCH RSI(14)
Neutral 33.12
MACD(12,26)
Bearish -28.93
ADX(14)
Weak Trend 19.07
UO(9)
Bearish 54.09
ROC(12)
Downtrend And Accelerating -5.44
WillR(14)
Neutral -37.51
About Divis Laboratories
Divi's Laboratories Ltd is a leading pharmaceutical company specializing in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals. The company operates globally with a presence in over 100 countries and has six manufacturing facilities. It offers both generic and custom synthesis services for pharmaceutical companies, supporting product development from clinical trials to market launch. Divi's Laboratories has two main subsidiaries: Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG, which focus on marketing nutraceutical products. The company has research centers in Hyderabad and at its manufacturing sites, with a focus on custom synthesis and contract research. Divi's Laboratories has expanded its operations over the years, establishing multiple manufacturing units, including special economic zones (SEZs), and has undergone various regulatory inspections and certifications. The company continues to invest in capacity expansion and infrastructure upgrades to meet growing market demands.
Listing Date
12 Mar, 2003(22 Years,
3 days)
Website
Chairperson NameRamesh B V Nimmagadda
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
